• where experts go to learn about FDA
  • Enforcement

    • HPM Attorneys to Present at FDLI’s Enforcement and Litigation ConferenceSeptember 29th, 2010

      Hyman, Phelps & McNamara, P.C.’s Douglas Farquhar and Ricardo Carvajal will be presenting at FDLI’s upcoming two-day conference on FDA enforcement and litigation.  Mr. Farquhar will moderate a panel on elements of proof in an injunction case, and will present on misdemeanors, debarment, and exclusion.    …

    • HP&M Presents the Evolution of FDA and the Park DoctrineSeptember 21st, 2010

      Join Hyman, Phelps & McNamara, P.C. attorneys on October 8, 12:00 p.m. – 1:30 p.m. for a free webinar on a very important, timely topic.  You can register for the free webinar here.  (Please register by September 29th.) In criminal prosecutions of corporate executives, ignorance of …

    • Cody/Lannett Unapproved Morphine Sulfate Litigation Gets New Legs; But FDA Motion to Dismiss Tries to Pull the Rug Out From Under ThemSeptember 6th, 2010

      By Kurt R. Karst –    The dispute between Cody Laboratories, Inc. and Lannett Co., Inc. (collectively “Cody/Lannett”) and FDA over marketed unapproved Morphine Sulfate Solution Immediate-Release 20mg/mL drug products did not end with the July 26, 2010 decision from the U.S. District Court for the District …

    • Veterinary Compounding Pharmacy Resumes Operations Despite FDA’s Attempt to Obtain a Preliminary InjunctionSeptember 2nd, 2010

      By William T. Koustas – Franck’s Lab, Inc. (“Defendant”), an Ocala, Florida veterinary compounding pharmacy, resumed compounding after a federal judge in the United States District Court for the Middle District of Florida denied the Government’s (“Plaintiff”) request for a preliminary injunction on August 19, 2010 that …

    • Responding To Recalls May Be a Walk in the Park for FDAAugust 29th, 2010

      By Oisin A. Mulvihill* & Peter M. Jaensch – A recent string of high-profile pharmaceutical and medical device product recalls appears to be reigniting FDA’s interest in pressing misdemeanor charges against corporate executives under the Responsible Corporate Officer Doctrine, or Park Doctrine. Lewis Grossman, professor …

    • Advertising and Promotion: FDA Is Not the Only Cop on the BeatAugust 19th, 2010

      In the July/August 2010 edition of FDLI Update, HP&M attorneys John R. Fleder and Cassandra A. Soltis authored an article, titled “Advertising and Promotion: FDA Is Not the Only Cop on the Beat.”  The article focuses on the various non-FDA groups that police alleged false …

    • Court Issues Ex Parte Temporary Restraining Order to Halt the Marketing of Acai Berry Weight-Loss Pills and Colon CleansersAugust 17th, 2010

      By Carrie S. Martin – Yesterday, the Federal Trade Commission (“FTC”) held a press conference in Chicago to announce a lawsuit against several companies, including Central Coast Nutraceuticals, iLife, Simply Naturals, Fit for Life, and Health and Beauty, for their marketing of acai berry weight-loss …

    • Another Advocacy Group Asks FDA to Increase Marketed Unapproved Drugs Enforcement CrackdownAugust 12th, 2010

      By Kurt R. Karst –    The 60 Plus Association, a senior advocacy group and alternative to AARP, has joined the debate over marketed unapproved drugs, asking FDA to step-up enforcement action and starting its “Keep Seniors Safe” initiative, which “advocates the removal of unapproved …

    • Regenerative Sciences Faced with FDA InjunctionAugust 11th, 2010

      By William T. Koustas – We have previously written that Regenerative Sciences (“Regenerative”), a Colorado-based stem cell company, filed a complaint in the U.S. District Court for the District of Columbia against FDA in order to enjoin it from regulating Regenerative’s use of cultured stem …

    • DDMAC re Facebook Share – Be Careful of What You Are SharingAugust 6th, 2010

      By Dara Katcher Levy - In what we believe is DDMAC’s first foray into tackling one of the “gray-areas” created by social media, on July 29, DDMAC issued an Untitled Letter to Novartis Pharmaceuticals for Rx drug content “grabbed” by a Facebook Share widget.  For those that …

    • Whistleblowers: A Potential Problem for EveryoneJuly 15th, 2010

      In the May/June 2010 edition of FDLI Update, HP&M Director John R. Fleder published his latest article on enforcement matters.  This article is entitled “Whistleblowers: Treat Them With Kid Gloves.”  The article addresses various issues that companies face when they are confronted with employees who …

    • Nestle Unit’s Settlement with FTC Contains New Provisions Regarding SubstantiationJuly 15th, 2010

      By Peter M. Jaensch – On July 14, 2010, the Federal Trade Commission (“FTC”) announced an agreement with Nestle HealthCare Nutrition, Inc. (“Nestle”) to settle an FTC investigation with regard to alleged false and misleading health claims. The FTC's Complaint arose from claims made by …

    • Compounding Pharmacies Strike back Against Government ActionsJuly 11th, 2010

      By John R. Fleder – It is hardly a secret that FDA’s favorite regulated industry is certainly not the businesses that compound pharmaceutical products.  For years FDA has struggled to establish an enforcement mechanism that passes muster with Congress and the courts.  Two compounding pharmacies have …

    • Advocacy Groups Ask FDA to Further Crack Down on Marketed Unapproved DrugsApril 20th, 2010

      By Kurt R. Karst –    In recent weeks, two advocacy groups have sent letters to FDA requesting that the Agency enhance and accelerate its enforcement activities with respect to marketed unapproved drugs.  FDA began its current Unapproved Drugs Initiative in June 2006 when the …

    • The Lanham Act: A Tool to Enforce the FDC Act?April 15th, 2010

      The March/April 2010 issue of FDLI Update contains an article by Hyman, Phelps & McNamara, P.C.’s Peter M. Jaensch and John R. Fleder that addresses the increasing number of cases brought under the federal Lanham Act law where plaintiffs have arguably sought to privately enforce the …